CA2432736A1 - Silenced anti-cd28 antibodies and use thereof - Google Patents
Silenced anti-cd28 antibodies and use thereof Download PDFInfo
- Publication number
- CA2432736A1 CA2432736A1 CA002432736A CA2432736A CA2432736A1 CA 2432736 A1 CA2432736 A1 CA 2432736A1 CA 002432736 A CA002432736 A CA 002432736A CA 2432736 A CA2432736 A CA 2432736A CA 2432736 A1 CA2432736 A1 CA 2432736A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- cells
- seq
- antibodies
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25515500P | 2000-12-14 | 2000-12-14 | |
US60/255,155 | 2000-12-14 | ||
PCT/US2001/047955 WO2002047721A1 (en) | 2000-12-14 | 2001-12-14 | Silensed anti-cd28 antibodies and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2432736A1 true CA2432736A1 (en) | 2002-06-20 |
Family
ID=22967074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002432736A Abandoned CA2432736A1 (en) | 2000-12-14 | 2001-12-14 | Silenced anti-cd28 antibodies and use thereof |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1341553A4 (ko) |
JP (1) | JP2004515243A (ko) |
KR (1) | KR20040020866A (ko) |
CN (1) | CN1272345C (ko) |
AR (1) | AR031924A1 (ko) |
AU (2) | AU2608602A (ko) |
BR (1) | BR0116686A (ko) |
CA (1) | CA2432736A1 (ko) |
CZ (1) | CZ20031909A3 (ko) |
HU (1) | HUP0400697A3 (ko) |
IL (1) | IL156262A0 (ko) |
MX (1) | MXPA03005327A (ko) |
NO (1) | NO20032542L (ko) |
NZ (1) | NZ526569A (ko) |
PL (1) | PL363239A1 (ko) |
RU (1) | RU2261723C2 (ko) |
WO (1) | WO2002047721A1 (ko) |
ZA (1) | ZA200305384B (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066059A2 (en) | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc | Agents that specifically block cd28-mediated signaling and uses therefor |
US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
PL2536764T3 (pl) * | 2010-02-18 | 2018-12-31 | Ose Immunotherapeutics | Humanizowane przeciwciała anty-CD28 |
CN114917185B (zh) | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CN113692286A (zh) * | 2019-03-14 | 2021-11-23 | 比昂生物制剂公司 | 一种用于免疫抑制的方法 |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024148336A1 (en) * | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | T cell costimulatory multimeric binding molecules and uses thereof |
US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580756A (en) * | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
-
2001
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Application Discontinuation
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Application Discontinuation
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA03005327A (es) | 2004-12-03 |
CN1489473A (zh) | 2004-04-14 |
ZA200305384B (en) | 2004-10-11 |
HUP0400697A3 (en) | 2007-05-02 |
AU2608602A (en) | 2002-06-24 |
RU2003121231A (ru) | 2005-02-10 |
WO2002047721A1 (en) | 2002-06-20 |
JP2004515243A (ja) | 2004-05-27 |
PL363239A1 (en) | 2004-11-15 |
CN1272345C (zh) | 2006-08-30 |
EP1341553A4 (en) | 2004-07-28 |
IL156262A0 (en) | 2004-01-04 |
AU2002226086B2 (en) | 2005-08-25 |
CZ20031909A3 (cs) | 2003-11-12 |
NO20032542L (no) | 2003-08-07 |
EP1341553A1 (en) | 2003-09-10 |
NO20032542D0 (no) | 2003-06-05 |
BR0116686A (pt) | 2003-12-30 |
HUP0400697A2 (hu) | 2004-06-28 |
AU2002226086C1 (en) | 2006-03-09 |
AR031924A1 (es) | 2003-10-08 |
KR20040020866A (ko) | 2004-03-09 |
RU2261723C2 (ru) | 2005-10-10 |
NZ526569A (en) | 2005-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0966485B1 (en) | MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME | |
RU2244720C2 (ru) | Антитело igg с аффинностью связывания в отношении антигенного комплекса cd3, рекомбинантные нуклеиновые кислоты, кодирующие легкую и тяжелую цепи антитела, способ получения системы, способ получения антитела, способ лечения пациента | |
AU2002226086B2 (en) | Silensed anti-CD28 antibodies and use thereof | |
US6129914A (en) | Bispecific antibody effective to treat B-cell lymphoma and cell line | |
JP4066166B2 (ja) | 抗−cd28抗体 | |
KR100191152B1 (ko) | Cd4 특이적 재조합 항체 | |
US20040052783A1 (en) | Humanized antibodies against CD3 | |
AU2002226086A1 (en) | Silensed anti-CD28 antibodies and use thereof | |
KR20050111748A (ko) | 면역억제 특성을 가진 인간화 항-cd4 항체 | |
WO1996032495A1 (en) | Monoclonal antibody specific for human 4-1bb and cell line producing same | |
AU2671699A (en) | Antibodies against human cd40 | |
KR20070036138A (ko) | 영장류에서 관용 유발을 위한 항-cd4 항체를 사용하는최적화 용량 결정 | |
MXPA01008098A (es) | Inmunoglobulina humanizada reactiva con moleculas b7 y metodo de tratamiento con el mismo. | |
US20040116675A1 (en) | Silenced anti-cd28 antibodies and use thereof | |
GB2376467A (en) | TRX1 Antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |